PD-L1
5 drugsProgrammed Death-Ligand 1
Predictive biomarker for patient selection in 9 indications
Understanding PD-L1
What it means: PD-L1 is a protein expressed by cancer cells that binds to PD-1 on T cells, suppressing immune response.
Why it matters: High PD-L1 expression often predicts better response to checkpoint inhibitors like pembrolizumab and nivolumab.
Testing: Tested via immunohistochemistry (IHC) with various scoring methods: TPS (Tumor Proportion Score) and CPS (Combined Positive Score).
5
Approved Drugs
9
Indications
4
Companies
PD-L1 is a precision-medicine biomarker linked to 5 FDA-approved targeted drugs from 4 companies, spanning 9 indications including Cutaneous Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer. Explore the targeted therapies, indications, testing methods, and companies developing PD-L1 drugs below.
Search PD-L1 Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting PD-L1
| Drug | Company | Therapeutic Area |
|---|---|---|
| BAVENCIO | EMD SERONO INC | Oncology |
| IMFINZI | AstraZeneca | Oncology |
| TECENTRIQ | Roche | Oncology |
| TECENTRIQ HYBREZA | Roche | Oncology |
| UNLOXCYT | CHECKPOINT THERAPEUTICS INC | Oncology |
PD-L1 Indications
Cutaneous Squamous Cell Carcinoma Non-Small Cell Lung Cancer Small Cell Lung Cancer Biliary Tract Cancer Metastatic Merkel cell carcinoma in adults and pediatric patients 12 years and older Maintenance treatment of locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy Locally advanced or metastatic urothelial carcinoma with disease progression during or following platinum-containing chemotherapy Locally advanced or metastatic urothelial carcinoma with disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy First-line treatment of advanced renal cell carcinoma in combination with axitinib